Clinical trial
A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
NCT05126303 is registered in ClinicalTrials.gov with Guard Therapeutics AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
- Lead sponsor
- Guard Therapeutics AB
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 31, 2022
- Completion date
- July 12, 2023
- Enrollment
- 177 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.